September 23, 2021
Acute Repetitive Seizures

Acute Repetitive Seizures Market to Record 46.7% CAGR Through 2027

Precedence Research has published a new report titled Acute Repetitive Seizures Market Size, Share By Product (NRL-1, Diastat Rectal Gel, USL-261, AZ-002 and Others) – Global Industry Analysis, Trends, Segment Forecasts, Regional Outlook 2020 – 2027″, the global acute repetitive seizures market size is expected to grow US$ 4.3 Billion by 2027, decelerating at a CAGR of over 46.7% from 2020 to 2027. The report contains 150+ pages with detailed analysis.

The global acute repetitive seizures market research report gives a brief summary of definitions, size analysis and place of production, sales, applications, types, and major players/key vendors of the acute repetitive seizures industry. The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.

This research study also integrates Industry Chain analysis and Porter’s Five Forces Analysis. Further, this report offers a competitive scenario that comprises collaborations, market concentration rate and expansions, mergers & acquisitions undertaken by companies. The report provides the overall revenue of the global acute repetitive seizures Market from 2016 to 2027, considering 2020 as the base year and 2027 as the forecast year.

Market Estimations:

Market Was Valued In 2019 US$ 180.3 Million
Market Is Projected To Grow By 2027 US$ 4.3 Billion
Compound Annual Growth Rate (CAGR) 46.7 percent from 2020 to 2027

Acute Repetitive Seizures Market Size 2016 to 2027

Acute repetitive seizures (ARS), status epilepticus, and autoimmune encephalitis are some neurologic traumas. For all these circumstances, suitable and rapid treatment may impact patient diagnosis and alleviate neuronal injury. Since past few years, there has been massive development in terms of the treatment and diagnosis of epilepsy, still in this context very smallemphasis has been given to acute repetitive seizures. The acute repetitive seizures stance a hazard of hospital admission with a mortality threat and status epilepticus, which underlines the necessity for the initial prophecy of a clinical course.

Prolonged seizures and acute repetitive seizures are considered as a neurological emergency and treatment must be rapid in such traumas. The principalaim of therapy are cessation of the seizure and deterrence of recurrence. There are numerous routes of drug administration, among all, nasal route is the most favored over others, like rectal, parenteral and buccal. The buccal route is chosen by parents and caregivers for kidsaffected with pediatric seizures subsequently medication can be directed even outside the hospital.The usage of conventional intravenous agents including phenobarbital, phenytoin, lorazepam and diazepam is well recognized in the first-line treatment of acute seizures. Nevertheless, adverse effects and the time to onset of consequence often dictate the choice amid older anticonvulsants.

Growth Factors

Increase in the number of clinical trials, a rise in emphasis on the introduction of new therapies, and the rise in requirement for nasal sprays for the treatment of epilepsy are the foremost reason influencing the development of acute repetitive seizures market across the globe. Furthermore, an intensification in the amount of supervisory approvals and promising drugs in the pipeline is expected to boost the growth of the acute repetitive seizures market within the prediction period. For illustration, in April 2018, UCB S.A. declared that the FDA acknowledged NDA for its nasal spray named Nayzilam (midazolam) designated for the treating seizures such as acute repetitive seizures and seizure clusters. This could result in the sanction of the drug in early 2019, make it the foremost ever medication permitted by the FDA in 17 years.

Additionally, in an effort to limit healthcare spending, governments are making incessant efforts to decrease hospital stays and on-site treatment costs by means of outpatient care models, like home healthcare and clinic. Developingnations including China are progressivelyemploying such healthcare modification, which is anticipated to push the growth of acute repetitive seizures marketplace.

Report Highlights

  • The market in the Asia Pacific is expected to expand at fastest CAGR during the forecast period driven by rising in awareness about the treatment of neurological disorders and increase in demand for new drug formulations for treating serious conditions in neurology
  • Europe is expected to offer substantial growth due to intensification in investment in research and development in the area of neurology, upsurge in funds obtainable by the government, and surge in demand for medications for epilepsy.
  • Germany is predicted to eye witness profitable growth during upcoming decade on account of rapid technological progressions in clinical, scientific, and medical sectors

COVID-19 Impact on acute repetitive seizures Market Sales

Businesses today are operating in a dynamic environment. Earlier focus primarily concentrated on keeping pace with changing consumer preferences. COVID-19 outbreak was unprecedented and exposed vulnerabilities of various industries. Pandemic-induces obstacles also were registered in the acute repetitive seizures market.

Sales plummeted as COVID-19 gradually tightened its noose worldwide. Supply-chain disruptions caused massive losses, while demand took nose-dive as consumers remained indoors with affected countries implementing either partial or complete lockdown.

Gradual recovery however is on the cards with the roll out of vaccinations. Nonetheless, consecutive waves of the virus compelled businesses to stay prepared for the worst. As government and healthcare organizations successfully implement steps to contain the spread of COVID-19, industries have begun operations, albeit at a slow and more cautious pace.

Against this backdrop, Precedence Research’s study predicts gradual recovery for the acute repetitive seizures market 2021 onwards. This trend will however continue through the course of the report’s assessment period.

Regional Snapshots

North America is anticipated to hold the considerable market stake throughout the prediction period. The U.S. seized a share more than 18% in 2019of the total market revenues. As per data released by the CDC, in 2014, about 750,000 children and 4.3 million grownups in the U.S. suffered from epilepsy. Further, the total indirect and direct cost of epilepsy in this region is assessed to be approximately USD 15.5 billion yearly. Consequently, the existence of a large target populace for epilepsy drugs in this region will fuel the growth of acute repetitive seizuresand epilepsy market.

Asia Pacific is also prospective to perceive speedy development due to cumulative healthcare spending in emerging nations including China and India. A huge gap was detected in the treatment for acute repetitive seizures in Asia Pacific. Henceforth, the demand for the antiseizure drugs in these emerging countries inspires a shift in market potential from the previously drenched North American and European regions to such economies.

Key Players & Strategies

Crucial participants operational in the acute repetitive seizures market are Neurelis, Inc., UCB S.A., Valeant Pharmaceuticals North America LLC and Alexza Pharmaceuticals. Neurelis, Inc. and UCB S.A. are expected to grasp the foremost take of the global market on account of the commercialization of VALTOCO and USL-261. As both the drugs (VALTOCO and USL-261) are approved orphan drug designation, the charges will be typically high. Further, favored route of administration is nasal, which in turn will cause greater acceptance of these two drugs.

Segments Covered in the Report

Product Outlook

  • NRL-1
  • Diastat Rectal Gel
  • USL-261
  • AZ-002
  • Others

Regional Outlook

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • South Africa
    • North Africa
    • Rest of Middle East & Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Acute Repetitive Seizures Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Acute Repetitive Seizures Market

5.1. Covid-19: Acute Repetitive Seizures Industry Impact
5.2. Acute Repetitive Seizures Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Acute Repetitive Seizures Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Acute Repetitive SeizuresMarket Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Acute Repetitive Seizures Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Upsurge in patient populace with status epilepticus and acute repetitive seizures
6.1.1.2. Emergence routes of administration for epileptic seizures and novel drug treatments
6.1.2. Market Restraints
6.1.2.1. Restraint 1
6.1.3. Market Opportunities
6.1.3.1. Opportunity 1
6.1.3.2. Opportunity 2

Chapter 7. Global Acute Repetitive Seizures Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Acute Repetitive Seizures Market Revenue by Market Players (2015-2020)
7.1.1.2. Acute Repetitive Seizures Market Revenue Market Share by Market Players (2015-2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Product Type Suppliers

Chapter 8. Global Acute Repetitive Seizures Market, By Product Type

8.1. Acute Repetitive SeizuresMarket, by Product Type, 2016-2027
8.1.1. NRL-1
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Diastat Rectal Gel
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. USL-261
8.1.3.1. Market Revenue and Forecast (2016-2027)
8.1.4. AZ-002
8.1.4.1. Market Revenue and Forecast (2016-2027)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2016-2027)

Chapter 9. Global Acute Repetitive Seizures Market, Regional Estimates and Trend Forecast

9.1. North America
9.1.1. Market Revenue Forecast by Product Type(2016-2027)
9.1.2. U.S
9.1.2.1. Market Revenue Forecast (2016-2027)
9.1.3. Canada
9.1.3.1. Market Revenue Forecast (2016-2027)
9.2. Europe
9.2.1. Market Revenue Forecast by Product Type(2016-2027)
9.2.2. UK
9.2.2.1. Market Revenue Forecast (2016-2027)
9.2.3. Germany
9.2.3.1. Market Revenue Forecast (2016-2027)
9.2.4. France
9.2.4.1. Market Revenue Forecast (2016-2027)
9.2.5. Rest of EU
9.2.5.1. Market Revenue Forecast (2016-2027)
9.3. Asia Pacific (APAC)
9.3.1. Market Revenue Forecast by Product Type(2016-2027)
9.3.2. China
9.3.2.1. Market Revenue Forecast (2016-2027)
9.3.3. India
9.3.3.1. Market Revenue Forecast (2016-2027)
9.3.4. Japan
9.3.4.1. Market Revenue Forecast (2016-2027)
9.3.5. Rest of APAC
9.3.5.1. Market Revenue Forecast (2016-2027)
9.4. LATAM
9.4.1. Market Revenue Forecast by Product Type(2016-2027)
9.4.2. Brazil
9.4.2.1. Market Revenue Forecast (2016-2027)
9.4.3. Rest of LATAM
9.4.3.1. Market Revenue Forecast (2016-2027)
9.5. Middle East and Africa (MEA)
9.5.1. Market Revenue Forecast by Product Type(2016-2027)
9.5.2. GCC
9.5.2.1. Market Revenue Forecast (2016-2027)
9.5.3. North Africa
9.5.3.1. Market Revenue Forecast (2016-2027)
9.5.4. South Africa
9.5.4.1. Market Revenue Forecast (2016-2027)
9.5.5. Rest of MEA
9.5.5.1. Market Revenue Forecast (2016-2027)

Chapter 10. Company Profiles

10.1. Neurelis, Inc.
10.1.1. Company Overview, Business Information, Regional Presence
10.1.2. Product Portfolio Analysis
10.1.2.1. Product Details, Specification, Application
10.1.3. Revenue, Price, and Gross Margin (2015-2020)
10.1.4. Recent Developments and Strategies
10.2. UCB S.A.
10.2.1. Company Overview, Business Information, Regional Presence
10.2.2. Product Portfolio Analysis
10.2.2.1. Product Details, Specification, Application
10.2.3. Revenue, Price, and Gross Margin (2015-2020)
10.2.4. Recent Developments and Strategies
10.3. Valeant Pharmaceuticals North America LLC
10.3.1. Company Overview, Business Information, Regional Presence
10.3.2. Product Portfolio Analysis
10.3.2.1. Product Details, Specification, Application
10.3.3. Revenue, Price, and Gross Margin (2015-2020)
10.3.4. Recent Developments and Strategies
10.4. Alexza Pharmaceuticals
10.4.1. Company Overview, Business Information, Regional Presence
10.4.2. Product Portfolio Analysis
10.4.2.1. Product Details, Specification, Application
10.4.3. Revenue, Price, and Gross Margin (2015-2020)
10.4.4. Recent Developments and Strategies
10.5. Company 5
10.5.1. Company Overview, Business Information, Regional Presence
10.5.2. Product Portfolio Analysis
10.5.2.1. Product Details, Specification, Application
10.5.3. Revenue, Price, and Gross Margin (2015-2020)
10.5.4. Recent Developments and Strategies
10.6. Company 6
10.6.1. Company Overview, Business Information, Regional Presence
10.6.2. Product Portfolio Analysis
10.6.2.1. Product Details, Specification, Application
10.6.3. Revenue, Price, and Gross Margin (2015-2020)
10.6.4. Recent Developments and Strategies
10.7. Company 7
10.7.1. Company Overview, Business Information, Regional Presence
10.7.2. Product Portfolio Analysis
10.7.2.1. Product Details, Specification, Application
10.7.3. Revenue, Price, and Gross Margin (2015-2020)
10.7.4. Recent Developments and Strategies
10.8. Company 8
10.8.1. Company Overview, Business Information, Regional Presence
10.8.2. Product Portfolio Analysis
10.8.2.1. Product Details, Specification, Application
10.8.3. Revenue, Price, and Gross Margin (2015-2020)
10.8.4. Recent Developments and Strategies
10.9. Company 9
10.9.1. Company Overview, Business Information, Regional Presence
10.9.2. Product Portfolio Analysis
10.9.2.1. Product Details, Specification, Application
10.9.3. Revenue, Price, and Gross Margin (2015-2020)
10.9.4. Recent Developments and Strategies
10.10. Company 10
10.10.1. Company Overview, Business Information, Regional Presence
10.10.2. Product Portfolio Analysis
10.10.2.1. Product Details, Specification, Application
10.10.3. Revenue, Price, and Gross Margin (2015-2020)
10.10.4. Recent Developments and Strategies

Chapter 11. Appendix

11.1. About Us
11.2. Glossary of Terms

Purchase This Premium Research Report @ https://www.precedenceresearch.com/checkout/1164

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semiconductors, chemicals, automotive, and aerospace & defense, among different ventures, present globally.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Bloghttps://precedenceresearchnews.wordpress.com

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

View all posts by Precedence Research →

Leave a Reply

Your email address will not be published. Required fields are marked *